{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000796","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.951934+00:00","generated_at":"2026-05-26T22:15:02.447617+00:00","sec_items":["1.01","5.03","3.02","3.03","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board","bullets":["Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.","Proceeds to fund Phase 2 study of EB06 (CXCL10 antibody) for nonsegmental vitiligo and for working capital.","Velan Capital led placement; officers/directors purchased ~$1.1M of securities.","David Liu, Senior Analyst at Velan Capital, appointed to Board of Directors effective immediately.","Company to file resale registration statement within 30 days; beneficial ownership cap of 4.99% (or 9.99% opt-in)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000796","json":"https://secwatch.observer/filing/0001171843-25-000796.json","markdown":"https://secwatch.observer/filing/0001171843-25-000796.md","text":"https://secwatch.observer/filing/0001171843-25-000796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/0001171843-25-000796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/f8k_021225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:15:02.447617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a75843ef5a","claim":"David Liu was appointed as Director at Edesa Biotech, Inc..","evidence_excerpt":"the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325000796/0001171843-25-000796-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}